Biovica’s DiviTum®TKa at ASCO

2022-05-09 13:15

Biovica, active in cancer diagnostics, today announces that the company's blood test DiviTum®TKa will be included in one oral presentation and two abstracts/posters, at the world's largest cancer congress, ASCO Annual Meeting, June 3-7, 2022, in Chicago, USA.

  • Results from BioItaLEE, an Italian multicenter study of metastatic BC, CDK4/6 inhibitors, 287 patients, DiviTum®TKa and ctDNA. The presentation will be held orally on June 6 in the largest hall, Clinical Science Symposium at 6:18 PM EDT / 00:18 CET 7th June. The title of the oral presentation is “Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial.
  • PREDIX study at the Karolinska Institute on 202 patients with locally advanced breast cancer will be presented as an abstract. The title of the abstract is “Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
  • A study performed by Imperial Collage and Royal Marsden Hospital, London, on 21 patients with Non-Small Cell Lung Cancer (NSCLC) treated with pemetrexed will be presented in a poster session. The title of the abstract is “[18F]fluorothymidine(FLT)-PET Imaging of thymidine kinase 1 pharmacodynamics in Non-Small Cell Lung Cancer treated with pemetrexed.

“We are proud that DiviTum®TKa is part of an oral presentation and two abstracts/posters at ASCO, the world’s largest cancer conference. Biovica is continuing to strengthen the clinical evidence for DiviTum®TKa within strategically important areas with well esteemed researchers. This will be a key success factor for clinical uptake of the product,” said Anders Rylander, CEO of Biovica.


Numbers of patients in studies




Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program